Pump_Image_tslimX2_Front_Straight_Actual_Size_DexcomG7
Predicts_
How to Order_2
Predictive software

Control-IQTM Technology

Predicting glucose levels 30 minutes ahead and suspending insulin, to help reduce the frequency and duration of lows.1*

CGM enabled

Dexcom G7 CGM Integration

Compatible with Dexcom G7 CGM requiring zero fingerpricks.†

Tandem green - Updateable

Updateable Platform

Capable of remote feature updates, instead of waiting for a whole new pump!

Tandem green - Updateable

Large, Colour Touchscreen

The t:slim X2 pump was designed to be user-friendly, with an easy-to-read, easy-to-use interface.

†If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

How Does Control-IQ™ Technology Work?

Interested in Control-IQ Technology?

Fill in the form below and one of our representatives will be in touch regarding the t:slim X2 pump and to help answer any of your questions!

Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources before purchasing. Consult your healthcare professional to see if this product is right for you.

*Additional feature updates are subject to future regulatory approvals. Basal-IQ and Control-IQ technology is not a substitute for active self-management of your diabetes. Basal-IQ technology is only available with Dexcom G6 CGM. Control-IQ technology is available with Dexcom G6 or G7 CGM. Dexcom CGM sold separately.
‡This application is for demonstration purposes only and is not identical to the functionality of the t:slim X2 pump. It should not be used for therapy decisions. To see which smart devices are compatible with the t:simulator App, please refer to the app’s full listing on The App Store and Google Play.

1. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. Predictive low-glucose suspend reduces hypoglycaemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161. doi:10.2337/dc18-0771.

Distributed in New Zealand by NZMS, 2a Fisher Crescent, Mt Wellington, Auckland, 1060.

Back to top